MNV
Market News Video
MNV MNV The 10 Most Popular Large-Caps in ETFs
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

AXDX Crosses Above Key Moving Average Level
Friday, June 26, 4:42 PM ET, by Market News Video Staff

In trading on Friday, shares of Accelerate Diagnostics Inc (AXDX) crossed above their 200 day ...

Notable Thursday Option Activity: MMM, THRM, AXDX
Thursday, July 2, 5:03 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

Accelerate Diagnostics Reaches Analyst Target Price
Monday, August 10, 8:58 AM ET, by Market News Video Staff

In recent trading, shares of Accelerate Diagnostics Inc (AXDX) have crossed above the average analyst ...

Notable Wednesday Option Activity: AXDX, AZO, PLUG
Wednesday, August 19, 3:16 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

AXDX Makes Notable Cross Below Critical Moving Average
Friday, August 21, 4:42 PM ET, by Market News Video Staff

In trading on Friday, shares of Accelerate Diagnostics Inc (AXDX) crossed below their 200 day ...

Accelerate Diagnostics: A 14.5% Better Bargain Than When Schuler Bought

By Market News Video Staff, Wednesday, March 24, 11:15 AM ET
Play Video: One Reason For Insiders to Buy


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on January 29, Accelerate Diagnostics Inc's Director, Jack W. Schuler, invested $314,236.24 into 30,868 shares of AXDX, for a cost per share of $10.18. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

In trading on Wednesday, bargain hunters could buy shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) and achieve a cost basis 14.5% cheaper than Schuler, with shares changing hands as low as $8.70 per share. Accelerate Diagnostics Inc shares are currently trading up about 0.8% on the day. The chart below shows the one year performance of AXDX shares, versus its 200 day moving average:

Accelerate Diagnostics Inc Chart

Looking at the chart above, AXDX's low point in its 52 week range is $6.82 per share, with $19.11 as the 52 week high point — that compares with a last trade of $8.90. By comparison, below is a table showing the prices at which AXDX insider buying was recorded over the last six months:

Purchased Insider Title Shares Price/Share Value
01/29/2021 Jack W. Schuler Director 30,868 $10.18 $314,236.24

Special Offer: Join the income investing conversation on ValueForum.com with a special Seven Days for Seven Dollars invitation.


This Article's Word Cloud:   AXDX   Accelerate   Back   Bargain   Bargains   Cheaper   Days   Diagnostics   Director   Dollars   Insider   Insiders   Jack   January   Join   Looking   Offer   Price   Purchased   Schuler   Seven   Share   Shares   Special   Start   Street   Than   There   Title   Value   ValueForum   about   below   buying   chart   cost   hunters   insider   last   only   point   reason   share   shares   stock   that   their   trading   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Chart Zero Stock Market Game Stock Market Definitions
MNV

Accelerate Diagnostics: A 14.5% Better Bargain Than When Schuler Bought | Market News Video | Copyright © 2008 - 2021, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.